
AffyXell Therapeutics
Founded Year
2020Stage
Corporate Minority - II | AliveTotal Raised
$7.3MAbout AffyXell Therapeutics
AffyXell Therapeutics provides biotechnology services. The company develops mesenchymal stem cells (MSCs) which are promising agents for the treatment of autoimmune and inflammatory diseases. AffyXell Therapeutics was founded in 2020 and is based in Gyeongsangnam-do, South Korea.
Latest AffyXell Therapeutics News
Jun 6, 2023
UK-based Avacta Group, a life sciences company developing targeted oncology drugs and powerful diagnostics, has announced that a second milestone equity payment has been triggered resulting in an increase in Avacta’s shareholding in AffyXell Therapeutics. Avacta’s Diagnostics division also recently completed the acquisition of Coris Bioconcept in Belgium as part of its growth strategy. South Korea […]
AffyXell Therapeutics Frequently Asked Questions (FAQ)
When was AffyXell Therapeutics founded?
AffyXell Therapeutics was founded in 2020.
Where is AffyXell Therapeutics's headquarters?
AffyXell Therapeutics's headquarters is located at 404, Gimhae Biomedical Industry Promotion Agency Techno Town, 80-59, Golden Route-ro, Juchon-myeon, Gimhae-si, , Gyeongsangnam-do.
What is AffyXell Therapeutics's latest funding round?
AffyXell Therapeutics's latest funding round is Corporate Minority - II.
How much did AffyXell Therapeutics raise?
AffyXell Therapeutics raised a total of $7.3M.
Who are the investors of AffyXell Therapeutics?
Investors of AffyXell Therapeutics include Avacta Group, Samsung Ventures, Stonebridge Ventures, Smilegate Investment, Gyeongnam Venture Investment and 6 more.